Esophageal Adenocarcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Esophageal Cancer (195)

Esophageal Squamous Cell Carcinoma (90)

Esophageal Cancer (195)

Esophageal Squamous Cell Carcinoma (90)

›

No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HER-2 overexpression	Esophageal Adenocarcinoma	HER-2 overexpression	Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
PD-L1 expression	Esophageal Adenocarcinoma	PD-L1 expression	Esophageal Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
HER-2 overexpression	Esophageal Adenocarcinoma	HER-2 overexpression	Esophageal Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2
MSI-H/dMMR	Esophageal Adenocarcinoma	MSI-H/dMMR	Esophageal Adenocarcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
RET fusion	Esophageal Adenocarcinoma	RET fusion	Esophageal Adenocarcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
BRAF V600E	Esophageal Adenocarcinoma	BRAF V600E	Esophageal Adenocarcinoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
MSI-H/dMMR	Esophageal Adenocarcinoma	MSI-H/dMMR	Esophageal Adenocarcinoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
MSI-H/dMMR	Esophageal Adenocarcinoma	MSI-H/dMMR	Esophageal Adenocarcinoma	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-H/dMMR	Esophageal Adenocarcinoma	MSI-H/dMMR	Esophageal Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 expression	Esophageal Adenocarcinoma	PD-L1 expression	Esophageal Adenocarcinoma	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
PD-L1 overexpression	Esophageal Adenocarcinoma	PD-L1 overexpression	Esophageal Adenocarcinoma	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
PD-L1 underexpression	Esophageal Adenocarcinoma	PD-L1 underexpression	Esophageal Adenocarcinoma	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	trastuzumab + pertuzumab Sensitive: C1 - Off-label trastuzumab + pertuzumab Sensitive : C1	trastuzumab + pertuzumab Sensitive: C1 - Off-label trastuzumab + pertuzumab Sensitive : C1
CLDN18.2 expression	Esophageal Adenocarcinoma	CLDN18.2 expression	Esophageal Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
HER-2 amplification	Esophageal Adenocarcinoma	HER-2 amplification	Esophageal Adenocarcinoma	trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria trastuzumab + avelumab Sensitive : C2	trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria trastuzumab + avelumab Sensitive : C2
PD-L1 expression	Esophageal Adenocarcinoma	PD-L1 expression	Esophageal Adenocarcinoma	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	paclitaxel Resistant: C3 – Early Trials paclitaxel Resistant : C3	paclitaxel Resistant: C3 – Early Trials paclitaxel Resistant : C3
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	carboplatin Resistant: C3 – Early Trials carboplatin Resistant : C3	carboplatin Resistant: C3 – Early Trials carboplatin Resistant : C3
ARID1A mutation	Esophageal Adenocarcinoma	ARID1A mutation	Esophageal Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
DKK1 overexpression	Esophageal Adenocarcinoma	DKK1 overexpression	Esophageal Adenocarcinoma	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3
DKK1 overexpression	Esophageal Adenocarcinoma	DKK1 overexpression	Esophageal Adenocarcinoma	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3
GRB7 positive	Esophageal Adenocarcinoma	GRB7 positive	Esophageal Adenocarcinoma	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3
HER-2 overexpression	Esophageal Adenocarcinoma	HER-2 overexpression	Esophageal Adenocarcinoma	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3
ERCC1 negative	Esophageal Adenocarcinoma	ERCC1 negative	Esophageal Adenocarcinoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3

Esophageal Adenocarcinoma

Associations(39)

Associations
(39)